Iqvia (NYSE: IQV) is one of 189 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Iqvia to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, analyst recommendations, risk and earnings.
Institutional and Insider Ownership
95.8% of Iqvia shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.4% of Iqvia shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Iqvia and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Iqvia has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Iqvia’s peers have a beta of 1.50, meaning that their average stock price is 50% more volatile than the S&P 500.
Earnings & Valuation
This table compares Iqvia and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Iqvia||$6.88 billion||$115.00 million||344.98|
|Iqvia Competitors||$217.40 million||-$39.40 million||-64.23|
Iqvia has higher revenue and earnings than its peers. Iqvia is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current ratings and target prices for Iqvia and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Iqvia currently has a consensus target price of $106.06, suggesting a potential upside of 6.02%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.22%. Given Iqvia’s peers stronger consensus rating and higher probable upside, analysts clearly believe Iqvia has less favorable growth aspects than its peers.
Iqvia beats its peers on 7 of the 13 factors compared.
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
What are top analysts saying about Iqvia? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Iqvia and related companies.